Healthcare provider resource center

HIV educational materials

Whether you have questions about universal screening, screening for specific therapies, or monitoring treatment, you’ll find expert answers and advice here, across the entire HIV care continuum. The links below take you to articles and live presentations covering both primary and specialty care topics. You may also contact one of our medical or technical directors below.

Looking for tools to help educate your patients about HIV testing and treatment? Have a peek at our Patient education tools page.

HIV Management–the evolving role of the primary care physician

Recommendations for universal screening of patients aged 13 to 64 highlight the growing role for PCPs in HIV care. Paul E. Sax, MD, Clinical Director, Division of Infectious Diseases, Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, reviews the role PCPs should play in HIV screening and diagnosis, and discusses the rationale for co-management of patients by PCPs and HIV infectious disease specialists.

The role of laboratory assays in the management of HIV

John Baxter, MD, of Robert Wood Johnson Medical School and Cooper University Hospital in Camden, NJ, discusses the role of laboratory testing in the diagnosis and treatment of HIV infection. Topics include current guidelines for initiation of retroviral therapy, how HIV-1 drug resistance occurs and its clinical consequences, differences between genotypic and phenotypic drug resistance testing, and the clinical utility of HIV-1 tropism assays.

Current issues and hot topics in HIV treatment & diagnostics

John Baxter, MD, Professor of Medicine, Division of Infectious Diseases, Robert Wood Johnson Medical School and Cooper University Hospital in Camden, NJ, summarizes updates to antiretroviral treatment guidelines featured in the U.S. DHHS revised “Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents,” 2011.

HIV tropism–next generation genotypic testing to predict virologic response

Dr. Rick Pesano, Medical Director, Infectious Diseases, Quest Diagnostics Nichols Institute, reviews recent research, which indicates that genotypic tropism testing, with reflex to ultradeep sequencing, may provide a valid alternative to phenotypic tests for determining viral tropism and subsequently predicting response to CCR5 coreceptor antagonist therapy.

HIV testing–genotypic technology in tropism and drug resistance testing

Dr. Jonathan Li, Infectious Disease Physician and Researcher, Brigham and Women’s Hospital, discusses how advances in genotypic testing technology offer healthcare providers a new option for tropism screening and enable an accurate prediction of virologic response to therapy.

HIV-1 infection diagnosis and management test guide

Download our test guide that provides an overview of the use of laboratory tests in the screening, diagnosis, and management of HIV infection.

HIV-1 infection ART selection test guide

Download our test guide that provides an overview of laboratory tests that, in the context of the patient’s clinical and laboratory history, may be useful in selecting components of ART regimen.

Quest Diagnostics and LabCorp HIV & HCV assay comparison table

Download our Quest Diagnostics and LabCorp HIV & HCV assay comparison table.

HIV-1 Coreceptor Tropism, Ultradeep Sequencing test summary

Download our test summary of the HIV-1 Coreceptor Tropism, Ultradeep Sequencing assay.

HIV reports

Consult with our HIV and HCV specialists

Gain additional clinical diagnostic insights by contacting one of our HIV/HCV testing consultants. They comprise one of the world’s most experienced infectious disease diagnostics teams and are available to answer your questions. To arrange a consultation or for more information, call Quest Diagnostics Client Services at 1.866.MYQUEST (1.866.697.8378).

ART=antiretroviral therapy; CCR5=C-C chemokine receptor type 5; DHHS=Department of Health and Human Services; HCV=hepatitis C virus; PCPs=primary care physicians; PI=protease inhibitor; RTI=reverse transcriptase inhibitor.